1887

Abstract

Decades after smallpox was eradicated and vaccination discontinued, the level of residual immunity in today's population is largely unknown. This study describes an epidemiological assessment in Italians of antibodies against the intracellular mature virus (IMV) and extracellular envelope virus (EEV) forms of . Serum samples (=642) were taken in 1993 and 2003 from people between 11 and 102 years old. Most citizens >27 years old were positive for antibodies to IMV and EEV. These antibodies were long-lasting and similar titres were present in citizens between 30 and 100 years old. Serum samples from 1993 and 2003 displayed very similar EEV- and IMV-specific antibody titres. By using these data and demographic considerations, it was predicted that, in 2003, 46 % of the Italian population were positive for both IMV and EEV, 42 % were negative for both and 12 % were positive for one antigen.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81265-0
2005-11-01
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/11/2955.html?itemId=/content/journal/jgv/10.1099/vir.0.81265-0&mimeType=html&fmt=ahah

References

  1. Aldaz-Carroll, L., Whitbeck, J. C., Ponce de Leon, M., Lou, H., Hirao, L., Isaacs, S. N., Moss, B., Eisenberg, R. J. & Cohen, G. H. ( 2005; ). Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol 79, 6260–6271.[CrossRef]
    [Google Scholar]
  2. Amara, R. R., Nigam, P., Sharma, S., Liu, J. & Bostik, V. ( 2004; ). Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78, 3811–3816.[CrossRef]
    [Google Scholar]
  3. Appleyard, G., Hapel, A. J. & Boulter, E. A. ( 1971; ). An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol 13, 9–17.[CrossRef]
    [Google Scholar]
  4. Bell, E., Shamim, M., Whitbeck, J. C., Sfyroera, G., Lambris, J. D. & Isaacs, S. N. ( 2004; ). Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325, 425–431.[CrossRef]
    [Google Scholar]
  5. Boulter, E. A. & Appleyard, G. ( 1973; ). Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol 16, 86–108.
    [Google Scholar]
  6. Combadiere, B., Boissonnas, A., Carcelain, G., Lefranc, E., Samri, A., Bricaire, F., Debre, P. & Autran, B. ( 2004; ). Distinct time effects of vaccination on long-term proliferative and IFN-γ-producing T cell memory to smallpox in humans. J Exp Med 199, 1585–1593.[CrossRef]
    [Google Scholar]
  7. Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L. & Ahmed, R. ( 2003; ). Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171, 4969–4973.[CrossRef]
    [Google Scholar]
  8. Davies, D. H., Liang, X., Hernandez, J. E. & 10 other authors ( 2005; ). Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A 102, 547–552.[CrossRef]
    [Google Scholar]
  9. Eichner, M. ( 2003a; ). Analysis of historical data suggests long-lasting protective effects of smallpox vaccination. Am J Epidemiol 158, 717–723.[CrossRef]
    [Google Scholar]
  10. Eichner, M. ( 2003b; ). Case isolation and contact tracing can prevent the spread of smallpox. Am J Epidemiol 158, 118–128.[CrossRef]
    [Google Scholar]
  11. el-Ad, B., Roth, Y., Winder, A., Tochner, Z., Lublin-Tennenbaum, T., Katz, E. & Schwartz, T. ( 1990; ). The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 161, 446–448.[CrossRef]
    [Google Scholar]
  12. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. ( 1988; ). Smallpox and its Eradication. Geneva: World Health Organization.
  13. Ferguson, N. M., Keeling, M. J., Edmunds, W. J., Gani, R., Grenfell, B. T., Anderson, R. M. & Leach, S. ( 2003; ). Planning for smallpox outbreaks. Nature 425, 681–685.[CrossRef]
    [Google Scholar]
  14. Fogg, C., Lustig, S., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H. & Moss, B. ( 2004; ). Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 78, 10230–10237.[CrossRef]
    [Google Scholar]
  15. Frey, S. E., Newman, F. K., Yan, L., Lottenbach, K. R. & Belshe, R. B. ( 2003; ). Response to smallpox vaccine in persons immunized in the distant past. JAMA 289, 3295–3299.[CrossRef]
    [Google Scholar]
  16. Gallwitz, S., Schutzbank, T., Heberling, R. L., Kalter, S. S. & Galpin, J. E. ( 2003; ). Smallpox: residual antibody after vaccination. J Clin Microbiol 41, 4068–4070.[CrossRef]
    [Google Scholar]
  17. Galmiche, M. C., Goenaga, J., Wittek, R. & Rindisbacher, L. ( 1999; ). Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254, 71–80.[CrossRef]
    [Google Scholar]
  18. Gani, R. & Leach, S. ( 2001; ). Transmission potential of smallpox in contemporary populations. Nature 414, 748–751.[CrossRef]
    [Google Scholar]
  19. Greenberg, R. N., Kennedy, J. S., Clanton, D. J., Plummer, E. A., Hague, L., Cruz, J., Ennis, F. A., Blackwelder, W. C. & Hopkins, R. J. ( 2005; ). Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 365, 398–409.[CrossRef]
    [Google Scholar]
  20. Hammarlund, E., Lewis, M. W., Hansen, S. G., Strelow, L. I., Nelson, J. A., Sexton, G. J., Hanifin, J. M. & Slifka, M. K. ( 2003; ). Duration of antiviral immunity after smallpox vaccination. Nat Med 9, 1131–1137.[CrossRef]
    [Google Scholar]
  21. Hanna, W. & Baxby, D. ( 2002; ). Studies in smallpox and vaccination. 1913. Rev Med Virol 12, 201–209.[CrossRef]
    [Google Scholar]
  22. Hatakeyama, S., Moriya, K., Saijo, M., Morisawa, Y., Kurane, I., Koike, K., Kimura, S. & Morikawa, S. ( 2005; ). Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations. Clin Diagn Lab Immunol 12, 520–524.
    [Google Scholar]
  23. Hooper, J. W., Custer, D. M. & Thompson, E. ( 2003; ). Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306, 181–195.[CrossRef]
    [Google Scholar]
  24. Kennedy, J. S., Frey, S. E., Yan, L., Rothman, A. L., Cruz, J., Newman, F. K., Orphin, L., Belshe, R. B. & Ennis, F. A. ( 2004; ). Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis 190, 1286–1294.[CrossRef]
    [Google Scholar]
  25. Law, M. & Smith, G. L. ( 2001; ). Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280, 132–142.[CrossRef]
    [Google Scholar]
  26. Law, M., Pütz, M. M. & Smith, G. L. ( 2005; ). An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 86, 991–1000.[CrossRef]
    [Google Scholar]
  27. McCarthy, K., Downie, A. W. & Bradley, W. H. ( 1958; ). The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J Hyg (Lond) 56, 466–478.[CrossRef]
    [Google Scholar]
  28. Pulford, D. J., Gates, A., Bridge, S. H., Robinson, J. H. & Ulaeto, D. ( 2004; ). Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22, 3358–3366.[CrossRef]
    [Google Scholar]
  29. Shooter, R. A. ( 1980; ). Report of the Investigation into the Cause of the 1978 Birmingham Smallpox Occurrence. London: HM Stationery Office.
  30. Smith, G. L. & McFadden, G. ( 2002; ). Smallpox: anything to declare? Nat Rev Immunol 2, 521–527.[CrossRef]
    [Google Scholar]
  31. Smith, G. L., Vanderplasschen, A. & Law, M. ( 2002; ). The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83, 2915–2931.
    [Google Scholar]
  32. Tagarelli, A., Piro, A. & Pasini, W. ( 2004; ). In Il vaiolo e la vaccinazione in Italia, vol. I, pp. 22–23. Consiglio Nazionale delle Ricerche; World Health Organization. Pieve Poligrafica Ed (in Italian).
  33. Vanderplasschen, A., Hollinshead, M. & Smith, G. L. ( 1997; ). Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 78, 2041–2048.
    [Google Scholar]
  34. Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R. B. & Smith, G. L. ( 1998; ). Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A 95, 7544–7549.[CrossRef]
    [Google Scholar]
  35. Viner, K. M. & Isaacs, S. N. ( 2005; ). Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect 7, 579–583.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81265-0
Loading
/content/journal/jgv/10.1099/vir.0.81265-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error